Nasdaq GlobeNewswire

Mitratech Yields Accolades as Market Leader and Innovator by Analyst Firm Hyperion Research

Del

Powerful "zero-code" product configuration, expansive user experience enhancements, and upgrades-included program set Mitratech's TeamConnect apart from other solution providers

AUSTIN, Texas, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Mitratech, a leading provider of legal, compliance, and risk management software solutions, today announced that its enterprise legal management (ELM) products have earned distinctions as Market Leaders and Highly Innovative products in the 2017 MarketView(TM) Report on Enterprise Legal Management by Hyperion Research, a leading analyst-based market research firm covering the ELM market.

Mitratech's years of investment in TeamConnect continues to deliver strong results - being one of the strongest products in the ELM market with top rankings across many of the rating categories in the MarketView(TM) Report. TeamConnect is the only ELM platform in the industry that includes code-free customizations, saving its clients significant time and money. And, its one-of-a-kind "upgrades-included" program demonstrates the company's true commitment to client success.

According to Hyperion, "TeamConnect, driven by aggressive development and a holistic vision of ELM in recent years, is one of the leading systems serving the enterprise market."1

"We are honored to be recognized as a Market Leader once again," said Mitratech CEO Jason Parkman. "We made the decision four years ago to pull ahead of all other ELM providers by offering something no one else can. It was a significant investment that is paying off for our clients today."

TeamConnect is one of three Mitratech products to make Hyperion's top ten and qualify as Advanced Solutions. Each Advanced Solution met all of Hyperion's Key Solution Components - fundamental requirements that define leading ELM practices for both e-billing and matter management. Twenty-three corporate legal department software products were evaluated with an opportunity to qualify for this distinction.

Hyperion validated Mitratech's vision to develop products that enable increased collaboration and communication between legal, compliance and risk professionals: "One of the things that distinguishes Mitratech from its competitors is its espoused worldview of ELM. Management contextualizes the discipline as part of a larger Governance, Risk and Compliance (GRC) universe, where risk management is perhaps as important as, or more important than, operational efficiency,"2 stated Hyperion.

Hyperion Research's MarketView(TM) report provides a comprehensive review of the broad market for Enterprise Legal Management technologies. The report provides a guidebook for ELM system evaluation, including market trends and dynamics, key components expected from leading solutions, an overview of vendors in the solution area, and guiding principles for selecting and implementing solutions.

The full report is available for download on the Hyperion website. For more information about Mitratech's products and services, visit www.mitratech.com.

ABOUT MITRATECH
Mitratech is a market-leading provider of legal, compliance, and risk software solutions for more than 1,200 organizations of all sizes across the globe, representing almost 40 percent of the Fortune 500, and over 500,000 users in over 160 countries. Mitratech's portfolio of enterprise legal and risk management software includes: legal matter management, spend management, e-Billing, legal hold, contracts management, risk management, policy management, audit management, and health & safety management. To learn more, visit www.mitratech.com.

ABOUT HYPERION RESEARCH
Hyperion Research is the industry's leading source for Legal Solutions Market Intelligence. We work with law firms, law departments and other legal service organizations to make intelligent, fact-based decisions about how to improve their operational performance. The profession's leaders, innovators and trend-makers have come to rely on Hyperion Research as the premier provider of independent market research, analysis and advisory services. We provide unparalleled insight to the leading trends in legal strategy, operations, and technology. Hyperion's analyst-based research and benchmarking informs 8 out of every 10 practice management system selections each year. For more information, visit www.hgpresearch.com.

__________________________________
1 2017, MarketView Legal Market Intelligence, Enterprise Legal Management E-Billing and Matter Management for Corporations, (page 100), Hyperion Research (elm.hgp-marketview.com).
2 2017, MarketView Legal Market Intelligence, Enterprise Legal Management E-Billing and Matter Management for Corporations, (page 101), Hyperion Research (elm.hgp-marketview.com).

Mitratech

Chris Kraft

512-382-7322




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Mitratech via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Novavax Continues Phase 3 Trial of the RSV F Vaccine for Infants via Maternal Immunization and Provides Update on Phase 1/2 Trial of the NanoFlu(TM) Vaccine18.12.2017 22:56Pressemelding

RSV F Vaccine informational analysis completed in fourth quarter of 2017 RSV F Vaccine interim analysis expected mid-2018 with approximately 4,600 enrollees Filing of RSV F Vaccine BLA anticipated by late 2019 NanoFlu Vaccine data package to be completed and released in February 2018 GAITHERSBURG, Md., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced the Phase 3 trial of its RSV F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal immunization will continue. Novavax also provided an update on its nanoparticle influenza vaccine candidate with proprietary Matrix-M(TM) adjuvant (NanoFlu(TM)). RSV F Vaccine for Infants via Maternal Immunization "Novavax has completed an informational analysis of our Phase 3 trial of the RSV F Vaccine for infants via maternal immunization using threshold criteria for a commercial product. As a result,

SD-WAN Market Leader, Aryaka, Releases First EMEA Edition of its State of SD-WAN Connectivity Report18.12.2017 15:06Pressemelding

Research finds up to 20x cloud and SaaS application performance improvements when connecting via private network-based SD-WANs versus the public Internet LONDON, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Aryaka®, the leading global SD-WAN provider, has released its first EMEA Edition of the State of SD-WAN Connectivity report that analyses the performance of SD-WAN deployments over the Internet as compared with those delivered over global private networks. The report highlights specific application response times between various European, Middle East, Asia-Pacific and Americas locations, as well as key factors that impact the performance of cloud and SaaS applications. This research helps IT leaders in Europe, Middle East and Africa (EMEA) to evaluate the best underlying connectivity for their SD-WAN deployments to ensure fast, reliable and consistent performance for all on-premises, cloud and SaaS applications, including voice, video, and data. The report reveals significant dif

Navigators to Acquire Belgian Specialty Insurer18.12.2017 07:30Pressemelding

STAMFORD, CT, December 18, 2017 - The Navigators Group, Inc. (NASDAQ:NAVG) today announced that it has entered into a share purchase agreement for the purchase of all of the shares of Assurances Continentales - Continentale Verzekeringen NV ("ASCO") and Bracht, Deckers & Mackelbert NV ("BDM").  ASCO and BDM are both based in Antwerp, Belgium. The proposed acquisition is part of Navigators' strategy of expanding its well-established specialty insurance expertise to more brokers and insureds across Europe. ASCO is a specialty insurance company offering marine and property and casualty insurance. BDM is an insurance underwriting agency that underwrites risk coverage in niche markets on behalf of ASCO and a number of major international insurers. Additionally, as part of the transaction, Navigators will acquire all the shares of Canal Re SA, a Luxembourg reinsurance company that is a wholly-owned subsidiary of ASCO.  The acquisition reinforces Navigators' presence in the European Un

Oxford Immunotec and QIAGEN N.V. Settle Patent Infringement Lawsuit15.12.2017 22:04Pressemelding

Agreement includes payment of $27.5 million to Oxford, royalty-free license to QIAGEN and dismissal of all pending litigation OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Ltd. (Nasdaq:OXFD) and QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt Stock Exchange:QIA) announced today that they have reached a settlement in the lawsuit in the U.S. District Court for the District of Massachusetts in Boston (15-cv-13124-NMG) alleging patent infringement in relation to QIAGEN's QuantiFERON®-TB Gold and QuantiFERON®-TB Gold Plus products. Under terms of the agreement, all pending claims between Oxford and QIAGEN and the co-defendants have been resolved. As part of the settlement, Oxford has granted QIAGEN a royalty-free, non-exclusive license that extends to all current and future customers of QuantiFERON-TB Gold and QuantiFERON-TB Gold Plus in exchange for a one-time, lump-sum payment of $27.5 million.  The settlement includes general

Algeco Scotsman Announces Acquisition of Iron Horse Ranch15.12.2017 21:32Pressemelding

BALTIMORE, Dec. 15, 2017 (GLOBE NEWSWIRE) -- Algeco/Scotsman Holding S.à r.l. (together with its subsidiaries, the "Algeco Group") today announced the successful closing of the acquisition by the Algeco Group's subsidiary, Target Logistics Management, LLC ("Target Logistics"), of Iron Horse Ranch from funds managed by TDR Capital LLP ("TDR"). The acquisition solidifies Target Logistics' position as the single largest provider of turnkey workforce housing in the U.S., including a network of eight lodges and 2,119 beds in the Permian Basin. With the acquisition, Target Logistics' Permian Basin lodge network now includes Texas lodges in Pecos, Mentone, San Angelo and two in Odessa, along with two lodges in Carlsbad and Lovington, New Mexico. Additionally, Target Logistics adds Eagle Ford lodges in Cameron and Yorktown, Texas. Diarmuid Cummins, CEO Algeco Scotsman: "Today we announce the completion of the second of two strategic acquisitions which we flagged earlier

Elemica Named to Food Logistics Top 100 List15.12.2017 13:55Pressemelding

11th Consecutive Win for Delivering Value Across Clients' Supply Chains WAYNE, Pa., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Elemica, the leading  Business Network for the process industries, announces the company has been named to Food Logistics magazine's FL100+ Award for the 11th year. The FL100+ list recognizes leading software and technology providers in the food and beverage industry.  Elemica was chosen for helping agricultural and food ingredient businesses conduct more efficient and error free commerce across their community of suppliers, customers and logistics providers - delivering value through lower operating expenses and working capital costs. "We are honored to be included for the past eleven years on the Food Logistics FL100+ list for helping companies improve efficiencies and generate value from their supply chains," said John Blyzinskyj, CEO of Elemica. "Automating business processes, enabling end-to-end visibility, and providing a platform for

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom